Aldeyra Therapeutics Income Statement (2013-2026) | ALDX

Income Statement Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
11.47M12.89M12.84M12.23M14.57M11.54M8.96M11.24M6.96M6.96M4.30M6.18M14.97M12.44M14.63M7.42M8.51M5.43M4.30M2.41M
Selling, General & Administrative (Quarter)
3.07M2.55M2.56M4.25M3.14M3.24M4.74M5.57M3.38M2.59M1.80M3.21M3.04M3.70M1.95M3.00M1.66M2.57M2.36M1.14M
Operating Expenses (Quarter)
14.54M15.44M15.40M16.48M17.71M14.78M13.70M16.80M10.34M9.55M6.10M9.39M18.01M16.14M16.58M10.43M10.17M8.00M6.67M3.55M
Operating Income (Quarter)
-14.54M-15.44M-15.40M-16.48M-17.71M-14.78M-13.70M-16.80M-10.34M-9.55M-6.10M-9.39M-18.01M-16.14M-16.58M-10.43M-10.17M-8.00M-6.67M-3.55M
EBIT (Quarter)
-14.54M-15.44M-15.40M-16.48M-17.71M-14.78M-13.70M-16.80M-10.34M-9.55M-6.10M-9.39M-18.01M-16.14M-16.58M-10.43M-10.17M-8.00M-6.67M-3.55M
Non-operating items
Interest & Investment Income (Quarter)
0.04M0.06M0.06M0.10M0.34M0.65M1.26M1.68M1.88M1.90M1.86M1.81M1.64M1.50M1.24M0.98M0.87M0.79M0.68M0.56M
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)
-0.39M-0.35M-0.35M-0.30M-0.07M0.23M0.79M1.19M1.36M1.36M1.34M1.31M1.16M1.02M0.77M0.50M0.40M0.31M0.21M0.09M
Net income details
EBT (Quarter)
-35.84M-27.38M-16.07M-18.58M-18.97M-19.03M-13.15M-41.50M-25.96M-15.18M-5.05M-8.08M-16.85M-22.02M-15.76M-17.60M-10.49M-14.02M-6.62M-3.45M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-14.94M-15.79M-15.75M-16.79M-17.78M-14.55M-12.88M-15.62M-8.99M-8.19M-4.75M-8.08M-16.85M-15.11M-15.86M-9.93M-9.77M-7.69M-6.46M-3.45M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)
-35.84M-27.38M-16.07M-18.58M-18.97M-19.03M-13.15M-41.50M-25.96M-15.18M-5.05M-8.08M-16.85M-22.02M-15.76M-17.60M-10.49M-14.02M-6.62M-3.45M
Consolidated Net Income (Quarter)
-35.84M-27.38M-16.07M-18.58M-18.97M-19.03M-13.15M-41.50M-25.96M-15.18M-5.05M-8.08M-16.85M-22.02M-15.76M-17.60M-10.49M-14.02M-6.62M-3.45M
Income towards Parent Company (Quarter)
-35.84M-27.38M-16.07M-18.58M-18.97M-19.03M-13.15M-41.50M-25.96M-15.18M-5.05M-8.08M-16.85M-22.02M-15.76M-17.60M-10.49M-14.02M-6.62M-3.45M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-35.84M-27.38M-16.07M-18.58M-18.97M-19.03M-13.15M-41.50M-25.96M-15.18M-5.05M-8.08M-16.85M-22.02M-15.76M-17.60M-10.49M-14.02M-6.62M-3.45M
Additional items
EPS (Basic) (Quarter)
-0.66-0.47-0.30-0.32-0.33-0.33-0.23-0.71-0.44-0.26-0.09-0.14-0.28-0.37-0.26-0.29-0.17-0.23-0.11-0.06
EPS (Diluted) (Quarter)
-0.66-0.47-0.30-0.32-0.33-0.33-0.23-0.71-0.44-0.26-0.09-0.14-0.28-0.37-0.26-0.29-0.17-0.23-0.11-0.06
Shares Outstanding (Quarter)
54.28M58.02M54.04M58.30M58.30M58.46M58.41M58.79M58.79M58.99M58.94M59.41M59.41M59.53M59.48M59.89M60.05M60.13M60.06M60.32M
Shares Outstanding (Diluted) (Quarter)
54.28M58.02M54.04M58.30M58.30M58.46M58.41M58.79M58.79M58.99M58.94M59.41M59.41M59.53M59.48M59.89M60.05M60.13M60.06M60.32M
EBITDA (Quarter)
-14.54M-15.44M-15.40M-16.48M-17.71M-14.78M-13.70M-16.80M-10.34M-9.55M-6.10M-9.39M-18.01M-16.14M-16.58M-10.43M-10.17M-8.00M-6.67M-3.55M
Interest Expenses (Quarter)
21.33M12.00M0.73M2.20M1.60M4.90M0.71M26.37M17.50M7.53M0.81M0.50M0.48M7.39M0.42M8.15M1.19M6.81M0.64M0.47M
Tax Rate (Quarter)